Types of arthritis: what the pattern tells you

What degenerative joint disease usually feels like

Degenerative joint disease is another name for osteoarthritis. It'll usually change a joint slowly over time. A knee may ache on steps. A hip may feel stiff after sitting.

Cartilage is the smooth cap at each bone end. Osteoarthritis can wear this covering thinner. Bone, the joint lining, and nearby muscles can change too. Like a worn door hinge, the whole joint may become stiff and noisy.

What to discuss at a joint visit

Tell the provider whether stiffness fades soon or lasts all morning. Point out warmth, swelling, skin changes, or matching sore joints. If you have notes from earlier visits, bring them. They'll keep the exam focused.

At QC Kinetix, medical providers examine the joint and review your health. They'll discuss non-surgical regenerative treatments that use your blood after clinic preparation. Ask what goes into the joint and who puts it there. Also ask what improvement you might notice.

When to ask about a different type

Rheumatoid disease starts when the immune system attacks joint lining. It often swells the same small joints on both sides. Gout can bring severe soreness within hours. These causes need different care from common joint wear.

Psoriasis causes red, scaly areas on the skin. When it also affects joints, doctors call the problem psoriatic disease. Nail changes or a whole swollen finger can occur too. Tell your doctor about those signs, even when the skin change seems small.

Sources

1. The 2010 ACR/EULAR classification criteria define 'definite rheumatoid arthritis' by confirmed synovitis in at least one joint, absence of a better alternative diagnosis, and a total score of 6 or more out of 10 across four domains: number and site of involved joints (0-5), serology (0-3), acute-phase response (0-1) and symptom duration (0-1). This is the formal boundary between inflammatory arthritis and degenerative joint disease.

   Aletaha D, et al. — 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.. Arthritis Rheum, 2010. DOI: 10.1002/art.27584.

2. The 2025 EULAR update recommends methotrexate, ideally combined with short-term glucocorticoids, as initial therapy for rheumatoid arthritis, within a treat-to-target strategy across conventional synthetic, biological and targeted synthetic DMARDs - a disease-modifying drug pathway that has no counterpart in osteoarthritis and which belongs to rheumatology.

   Smolen JS, et al. — EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update.. Ann Rheum Dis, 2026. DOI: 10.1016/j.ard.2026.01.023.

3. The 2020 ACR gout guideline issued 42 recommendations including 16 strong ones: start urate-lowering therapy for anyone with tophaceous gout, radiographic damage from gout or frequent flares; allopurinol first-line including in moderate-to-severe chronic kidney disease; low starting doses; and treat-to-target dose titration to a serum urate below 6 mg/dL. Gout is treatable to target in a way osteoarthritis is not.

   FitzGerald JD, et al. — 2020 American College of Rheumatology Guideline for the Management of Gout.. Arthritis Care Res (Hoboken), 2020. DOI: 10.1002/acr.24180.

4. CDC's National Health Interview Survey analysis found an estimated 21.2% of US adults (53.2 million people) had doctor-diagnosed arthritis in 2019-2021. Age-standardised prevalence was higher in women (20.9%) than men (16.3%). Adults 45 and older make up 88.3% of all US adults with arthritis, and prevalence was high among people with COPD (57.6%), dementia (55.9%), stroke (52.6%), heart disease (51.5%), diabetes (43.1%) and cancer (43.1%).

   Fallon EA, et al. — Prevalence of Diagnosed Arthritis - United States, 2019-2021.. MMWR Morb Mortal Wkly Rep, 2023. DOI: 10.15585/mmwr.mm7241a1.